Tianjin Tianyao Pharmaceuticals Co., Ltd.

Shanghai Stock Exchange 600488.SS

Tianjin Tianyao Pharmaceuticals Co., Ltd. Market Capitalization on January 27, 2025: USD 635.32 M

Tianjin Tianyao Pharmaceuticals Co., Ltd. Market Capitalization is USD 635.32 M on January 27, 2025, a -4.38% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Tianjin Tianyao Pharmaceuticals Co., Ltd. 52-week high Market Capitalization is USD 710.70 M on December 16, 2024, which is 11.86% above the current Market Capitalization.
Tianjin Tianyao Pharmaceuticals Co., Ltd. 52-week low Market Capitalization is USD 498.89 M on February 07, 2024, which is -21.47% below the current Market Capitalization.
Tianjin Tianyao Pharmaceuticals Co., Ltd. average Market Capitalization for the last 52 weeks is USD 603.40 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

Shanghai Stock Exchange: 600488.SS

Tianjin Tianyao Pharmaceuticals Co., Ltd.

CEO	Mr. Shuxiang Li
IPO Date	June 18, 2001
Location	China
Headquarters	No. 19, Xinye 9th Street
Employees	2,678
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Chemicals & Advanced Materials Drugstores & Retail Pharmacies Personal Care Petrochemicals Plastics

Description

Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research, manufacture, and export of pharmaceutical APIs in Asia. It primarily provides corticosteroid, cardio cerebrovascular, and analgesic APIs and formulations. The company offers bulk drugs, including dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate, triamcinlone acetonide acetate, prednisone acetate, prednisone, prednisolone, flucinonide, halcinonide, triamcinolone acetonide, clobetasol propionate, betamethasone, methylprednisolone hydrocortisone acetate, methylprednisolone, and triamcinolone. The company is based in Tianjin, China. Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE : 600488) operates as a subsidiary of Jinhushen Biomedical Technology Co., Ltd.

Key trends

Past 5 years